Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Bumps DeCode from Global Market

NEW YORK (GenomeWeb News) — DeCode Genetics' stock has been moved from the Nasdaq Global Market to the Nasdaq Capital Market after failing to maintain a minimum market value for listed shares, the company said today.

Nasdaq decided to move DeCode to the Capital Market, which is one of three Nasdaq tiers, after a review hearing on Dec. 18, 2008, regarding its non-compliance with the market's rules.

The move to the Capital Market took effect this morning and the company will continue to be listed there, under the same market symbol (DCGN), until a review process is completed by April 29.

The company's stock was trading at $.22 per share this morning, and its current market capitalization is around $13.6 million.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.